These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35759947)

  • 1. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
    Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
    Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
    Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
    Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
    Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
    Vranceanu AM; Merker VL; Park E; Plotkin SR
    J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
    Brown R
    Curr Oncol Rep; 2023 Dec; 25(12):1409-1417. PubMed ID: 37906356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
    Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
    Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
    Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
    Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
    Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
    Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
    BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
    Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
    Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from drug trials in neurofibromatosis: A systematic review.
    Dhaenens BAE; Ferner RE; Evans DG; Heimann G; Potratz C; van de Ketterij E; Kaindl AM; Hissink G; Carton C; Bakker A; Nievo M; Legius E; Oostenbrink R
    Eur J Med Genet; 2021 Sep; 64(9):104281. PubMed ID: 34237445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
    Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
    Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
    Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diagnosis and Management of Neurofibromatosis Type 1.
    Ly KI; Blakeley JO
    Med Clin North Am; 2019 Nov; 103(6):1035-1054. PubMed ID: 31582003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schwannomatosis: a Realm Reborn: year one.
    Planet M; Kalamarides M; Peyre M
    Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
    Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
    Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.